The emerging role of lapatinib in HER2-positive breast cancer

Alice Ulhoa-Cintra, Larisa Greenberg, Charles E. Geyer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalCurrent Oncology Reports
Volume10
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Breast Neoplasms
Anthracyclines
Paclitaxel
Clinical Trials
Phenotype
Drug Therapy
Therapeutics
Neoplasms
lapatinib
Capecitabine
Trastuzumab
taxane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The emerging role of lapatinib in HER2-positive breast cancer. / Ulhoa-Cintra, Alice; Greenberg, Larisa; Geyer, Charles E.

In: Current Oncology Reports, Vol. 10, No. 1, 01.2008, p. 10-17.

Research output: Contribution to journalArticle

Ulhoa-Cintra, Alice ; Greenberg, Larisa ; Geyer, Charles E. / The emerging role of lapatinib in HER2-positive breast cancer. In: Current Oncology Reports. 2008 ; Vol. 10, No. 1. pp. 10-17.
@article{49a8ebd0296f4940b1c7e752fffb2079,
title = "The emerging role of lapatinib in HER2-positive breast cancer",
abstract = "In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.",
author = "Alice Ulhoa-Cintra and Larisa Greenberg and Geyer, {Charles E.}",
year = "2008",
month = "1",
doi = "10.1007/s11912-008-0004-0",
language = "English (US)",
volume = "10",
pages = "10--17",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - The emerging role of lapatinib in HER2-positive breast cancer

AU - Ulhoa-Cintra, Alice

AU - Greenberg, Larisa

AU - Geyer, Charles E.

PY - 2008/1

Y1 - 2008/1

N2 - In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

AB - In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=38149058790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149058790&partnerID=8YFLogxK

U2 - 10.1007/s11912-008-0004-0

DO - 10.1007/s11912-008-0004-0

M3 - Article

VL - 10

SP - 10

EP - 17

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 1

ER -